ESTRO 2026 | Can IMRT alone be used for higher-risk oropharyngeal cancer?

Satoaki Nakamura • 16 May 2026

ESTRO 2026

Head and Neck Cancer

Satoaki Nakamura, MD, PhD, FJCR, Kansai Medical University, Hirakata, Japan, explores whether intensity-modulated radiotherapy (IMRT) alone could be used for intermediate or higher-risk oropharyngeal cancer. The JCOG1208 trial of IMRT alone carefully selected only early-stage patients, and Dr Nakamura cautions against applying these results to patients with bulky tumors, advanced nodal disease or other high-risk features. This interview took place at the European Society for Radiotherapy and Oncology 2026 Congress in Stockholm, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.